NASDAQ:CERS

Cerus - CERS Stock Forecast, Price & News

$3.80

+0.01 (+0.26%)

(As of 10/6/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.73
▼
$3.86
50-Day Range: $3.43
▼
$5.83
52-Week Range: $3.39
▼
$8.06

Volume: 1.11 million shs
Average Volume: 1.77 million shs
Market Capitalization: $672.94 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Cerus MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
4.03% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$51,200 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.21) to ($0.18) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Medical Sector

993rd out of 1,075 stocks

Surgical & Medical Instruments Industry

95th out of 104 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Cerus.

3.0

Short Interest

Percentage of Shares Shorted
4.03% of the float of Cerus has been sold short.
Short Interest Ratio / Days to Cover
Cerus has a short interest ratio ("days to cover") of 4.3.
Change versus previous month
Short interest in Cerus has recently decreased by 2.27%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Cerus does not currently pay a dividend.
Dividend Growth
Cerus does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CERS.

1.9

News and Social Media Coverage

News Sentiment
Cerus has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Cerus this week, compared to 2 articles on an average week.
Search Interest
9 people have searched for CERS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cerus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $51,200.00 in company stock.
Percentage Held by Insiders
Only 7.33% of the stock of Cerus is held by insiders.
Percentage Held by Institutions
84.72% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cerus are expected to grow in the coming year, from ($0.21) to ($0.18) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cerus is -15.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cerus is -15.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cerus has a P/B Ratio of 7.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cerus (NASDAQ:CERS) Stock

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

CERS Stock News Headlines

October 2, 2022 | fool.com

Cerus (NASDAQ: CERS)

September 29, 2022 | seekingalpha.com

Cerus Stock: Technical Support Fades, Investment Case Weakens (NASDAQ:CERS) - Seeking Alpha

September 29, 2022 | nasdaq.com

Does Cerus (NASDAQ:CERS) Have A Healthy Balance Sheet?

September 26, 2022 | benzinga.com

Cerus Corporation Announces Workshop and Abstracts at the 2022 AABB Annual Meeting - Cerus (NASDAQ:CERS) - Benzinga

September 26, 2022 | finance.yahoo.com

Cerus Corporation Announces Workshop and Abstracts at the 2022 AABB Annual Meeting

September 21, 2022 | finance.yahoo.com

After Plunging 17.6% in 4 Weeks, Here's Why the Trend Might Reverse for Cerus (CERS)

September 19, 2022 | finance.yahoo.com

Cerus Corporation (CERS)

September 14, 2022 | finance.yahoo.com

Investors in Cerus (NASDAQ:CERS) have made a decent return of 59% over the past five years - Yahoo Finance

September 14, 2022 | finance.yahoo.com

Investors in Cerus (NASDAQ:CERS) have made a decent return of 59% over the past five years

September 13, 2022 | nasdaq.com

Zimmer (ZBH) Surges 4.2%: Is This an Indication of Further Gains? - Nasdaq

September 11, 2022 | reuters.com

CERS.O - Cerus Corporation | Stock Price & Latest News | Reuters

September 10, 2022 | reuters.com

CERS.OQ - Cerus Corporation | Stock Price & Latest News | Reuters

September 6, 2022 | streetinsider.com

Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer - StreetInsider.com

September 1, 2022 | globenewswire.com

Blood Purification Devices Market Size Will Achieve USD - GlobeNewswire

August 29, 2022 | nasdaq.com

Down 20.4% in 4 Weeks, Here's Why Cerus (CERS) Looks Ripe for a Turnaround - Nasdaq

August 29, 2022 | finance.yahoo.com

Down 20.4% in 4 Weeks, Here's Why Cerus (CERS) Looks Ripe for a Turnaround

August 22, 2022 | nasdaq.com

Relative Strength Alert For Cerus Corp. - Nasdaq

August 17, 2022 | benzinga.com

Cerus Earnings Perspective: Return On Capital Employed - Benzinga

August 12, 2022 | businesswire.com

Cerus Corporation Acknowledges Growing Monkeypox Outbreak and Public Health Emergency - Business Wire

August 12, 2022 | finance.yahoo.com

Cerus Corporation Acknowledges Growing Monkeypox Outbreak and Public Health Emergency

August 5, 2022 | fool.com

Cerus (CERS) Q2 2022 Earnings Call Transcript - The Motley Fool

August 5, 2022 | finance.yahoo.com

Cerus (CERS) Q2 2022 Earnings Call Transcript

August 5, 2022 | seekingalpha.com

Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M (NASDAQ:CERS) - Seeking Alpha

August 4, 2022 | finance.yahoo.com

Cerus Corporation Announces Another Record Quarter and Reiterates Full Year 2022 Product Revenue Guidance Range - Yahoo Finance

August 4, 2022 | businesswire.com

Cerus Corporation Announces Another Record Quarter and Reiterates Full Year 2022 Product Revenue Guidance Range - Business Wire

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter.

CERS Company Calendar

Last Earnings: 8/04/2022
Today: 10/07/2022
Next Earnings (Estimated): 11/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Supplies
Sector: Medical
Current Symbol: NASDAQ:CERS
CUSIP: 15708510
CIK: 1020214
Web: www.cerus.com
Phone: (925) 288-6000
Fax: 925-288-6001
Employees: 631
Year Founded: 1991

Profitability

EPS (Most Recent Fiscal Year): ($0.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-54,380,000.00
Net Margins: -27.34%
Pretax Margin: -27.16%
Return on Equity: -52.16%
Return on Assets: -18.88%

Debt

Debt-to-Equity Ratio: 0.53
Current Ratio: 2.08
Quick Ratio: 1.73

Sales & Book Value

Annual Sales: $130.86 million
Price / Sales: 5.14
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.50 per share
Price / Book: 7.60

Miscellaneous

Outstanding Shares: 177,090,000
Free Float: 164,109,000
Market Cap: $672.94 million
Optionable: Optionable
Beta: 1.15

Social Links

Key Executives

Mr. William M. Greenman (Age 55)
Pres, CEO & Director
Comp: $1.25M

Dr. Laurence M. Corash (Age 78)
Co-Founder & Chief Scientific Officer
Comp: $697.77k

Mr. Kevin D. Green (Age 50)
VP of Fin. & CFO
Comp: $698.15k

Mr. Vivek K. Jayaraman (Age 47)
Chief Operating Officer
Comp: $845.3k

Dr. Richard J. Benjamin (Age 62)
Chief Medical Officer
Comp: $718.64k

Ms. Lori L. Roll
VP of Admin. & Corp. Sec.

Mr. Matthew M. Notarianni
Sr. Director of Investor Relations

Ms. Chrystal N. Menard (Age 51)
Chief Legal Officer & Gen. Counsel

Lainie Corten
VP of Global Marketing

Ms. Carol M. Moore (Age 72)
Sr. VP of Regulatory Affairs, Quality & Clinical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CERS Stock - Frequently Asked Questions

How have CERS shares performed in 2022?: Cerus' stock was trading at $6.81 at the beginning of the year. Since then, CERS stock has decreased by 44.2% and is now trading at $3.80.
View the best growth stocks for 2022 here.
When is Cerus' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our CERS earnings forecast.
How were Cerus' earnings last quarter?: Cerus Co. (NASDAQ:CERS) announced its quarterly earnings data on Thursday, August, 4th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. The biotechnology company had revenue of $41 million for the quarter, compared to analyst estimates of $40 million. Cerus had a negative trailing twelve-month return on equity of 52.16% and a negative net margin of 27.34%.
What guidance has Cerus issued on next quarter's earnings?: Cerus issued an update on its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $160.00 million-$165.00 million, compared to the consensus revenue estimate of $176.65 million.
What is William M. (Obi) Greenman's approval rating as Cerus' CEO?: 15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cerus own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).
What is Cerus' stock symbol?: Cerus trades on the NASDAQ under the ticker symbol "CERS."
How do I buy shares of Cerus?: Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cerus' stock price today?: One share of CERS stock can currently be purchased for approximately $3.80.
How much money does Cerus make?: Cerus (NASDAQ:CERS) has a market capitalization of $672.94 million and generates $130.86 million in revenue each year. The biotechnology company earns $-54,380,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.
How many employees does Cerus have?: The company employs 631 workers across the globe.
How can I contact Cerus?: Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The official website for the company is www.cerus.com. The biotechnology company can be reached via phone at (925) 288-6000, via email at ir@cerus.com, or via fax at 925-288-6001.

This page (NASDAQ:CERS) was last updated on 10/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cerus - CERS Stock Forecast, Price & News

Cerus MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month